Document Classification

Section Type: METHODS

Text: Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5. 0 mg/m (2) by intravenous (IV) infusion over 30 minutes on days 1 to 5 with ara-C 1. 0 g/m (2) / d IV [DOSAGE ERROR CORRECTED] over 2 hours on days 1 to 5, idarubicin 12 mg/m (2) by 5 minute IV infusion on days 1 to 3, or topotecan 1. 0 mg/m (2) as an continuous IV infusion on days 1 to 5.